Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20173786 | 0.89 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP1A2GRIA2CYP3A4 | |
| SCHEMBL20178628 | 0.81 | CYP11B2 (0.59) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20178639 | 0.76 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20178692 | 0.76 | CYP11B1 (0.44) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21217003 | 0.74 | SIGMAR1 (0.39) | NAMPT | |
| SCHEMBL6370155 | 0.70 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31070625 | 0.69 | GPR119 (0.53) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8081400 | 0.69 | CYP11B2 (1.00) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20178634 | 0.69 | MEN1 (0.52) | — | |
| SCHEMBL31070593 | 0.68 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | CYP11B1 268/4885CYP11B2 336/4885CYP1A2 431/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | CYP11B1 268/4885CYP11B2 336/4885CYP1A2 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.